Anti-Human PD-1 (Cemiplimab Biosimilar)
Catalog #500013
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500013 | 1 mg | $200.00 | ||
| 500013 | 5 mg | $600.00 | ||
| 500013 | 20 mg | $1,400.00 |
Product Details
Cemiplimab biosimilar is a fully human IgG4 monoclonal antibody targeting programmed death receptor-1 (PD-1). It is developed as a cost-effective alternative to the reference biologic Cemiplimab (Libtayo®), maintaining comparable efficacy, safety, and quality. This biosimilar is intended for preclinical and translational research in immuno-oncology, particularly in the study of cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC), and other solid tumors.
Specifications
| Clone | Cemiplimab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG4 |
| Recommended Isotype Control | Human IgG4 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 7.4 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human PD1 |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |